• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    New uracil derivatives of the general formula: <IMAGE> wherein R1 stands for a hydrogen atom or a grouping of the formula: <IMAGE> R2 for a hydrogen atom, an alkyl group or a phenyl group and R3 for an alkyl group or a phenyl group, with the proviso that when both R1 and R2 stand for a hydrogen atom, R3 stands for a phenyl group or a straight chain alkyl group with 3 DIFFERENCE 11 carbon atoms, that when R1 stands for a hydrogen atom and R2 for methyl group, R3 stands for an alkyl group with at least 2 carbon atoms or a phenyl group, and that when R1 stands for a hydrogen atom and R3 for methyl group, R2 stands for an alkyl group with at least 2 carbon atoms or a phenyl group. These uracil derivatives are prepared by reacting 5-fluorouracil with an alpha -haloalkyl carboxylate or with an aldehyde diacylate or by hydrolyzing a 1,3-bis(acyloxymethyl)-5-fluorouracil with an acid or alkali. These uracil derivatives are useful as improved anti-tumor agents especially for oral administration and injection.
    公开号:SU795468A3
    申请号:SU772521748
    申请日:1977-09-06
    公开日:1981-01-07
    发明作者:Озаки Соитиро；Ике Есимаза；Исикава Кацутоси；Тамура Харуки
    申请人:Мицуи Тоацу Кемикалз Инкорпо-Рейтед (Фирма)；
    IPC主号:
    专利说明:

    or isolated as a target, product, or hydrolyzed by the action of an acid or alkali to obtain compounds of formula 1, where R is hydrogen.
    Chloromethyl acetate, an example is chloromethyl propionate (or propionyloxymethyl chloride), chloromethyl butyrate, chloromethyl capronate, chloromethyl naphlate, chloromethyl palaurate, chloromethyl palmate, chloromethyl pelovate or chloromethyl carbonate.
    The reaction is preferably carried out in the presence of an acid binding agent and a normally liquid polar solvent, which is inert to the reaction, but has the ability to dissolve the starting materials. In general, 5-fluorouracil and about -haloalkylcarboxylate are miscible or easily dissolved in a similar polar solvent. Examples of polar solvents include N, N-dialkylcarboxylamides, dimethylformamide, dimethylacetamide, and dialkyl sulphoxides such as dimethyl sulphoxide. Acetonitrile can also be used as a solvent.
    Preferred acid binding agents are inorganic bases, such as alkali metal hydroxides, alkali metal hydrides, alkali metal carbonates and bicarbonates, and organic bases such as aliphatic and aromatic tertiary amines, and also tetraalkyl ammonium hydroxides. Sodium hydride, potassium carbonate, triethylamine and pyridine are preferably used. If the reagents are soluble in a similar aliphatic or aromatic tertiary amine, then part or all of the polar solvent can be replaced with such a tertiary amine.
    The reaction is preferably carried out in a temperature range from 0 to, preferably in ambient temperature to. The reaction time depends on the reaction temperature chosen and is 120 hours, preferably 2-10 hours.
    At the end of the condensation reaction, the desired substance is injected and purified by general-quality methods, preferably by chromatographic processing. The reaction liquid is filtered to isolate insoluble substances consisting mainly of an inorganic salt or a tertiary amine hydrogene, after which the solvent used is removed by distillation, preferably under atmospheric pressure. The distillation residue is subjected to chromatographic treatment carried out on a silica gel column as a pad; A mixture of benzene and ethyl acetate is used as a solvent. This treatment achieves the separation of the crude final product from the 3-substituted isomer, formed as a by-product, and from the unreacted starting materials. The distillation residue is taken up in chloroform and the solution in chloroform is filtered to remove insoluble 5-fluorouracil, washed with water and dried. After removal of chloroform by distillation, a crude end product is obtained. In some cases, the reaction product can be poured into water, in which the inorganic salt or tertiary amine hydrohalide formed during the condensation reaction dissolves, and water-insoluble substances, including the final product, precipitate. The crude final product thus obtained can be purified by recrystallization from benzene,
    5 ethanol or ether, or by dissolving the crude product in chloroform and pouring the solution into a solvent in which the product does not dissolve.
    To hydrolyze Nj (, substituted
    0 uracil formula 1.1 I preferably use a strong inorganic acid or its aqueous solution, or caustic alkali, or its aqueous solution and process is carried out preferably at a temperature from 0 to 1-10 hours.
    Strong inorganic acid, such as hydrochloric or sulfuric, as well as their aqueous solutions, which may contain miscible.
     with water, an organic polar solvent, can be used as an acid for hydrolysis. A strong inorganic base, such as caustic alkali, can be used.
    5 as an alkali for hydrolysis a. It is particularly preferable to use an aqueous solution of caustic alkali, for example, an aqueous solution of caustic soda, which may contain
    0 water with an organic solvent, such as ethanol.
    The hydrolysis reaction as an optional treatment is usually carried out by dissolving the original
    5 A disubstituted product of general formula (III) in a solvent, slowly adding acid to the solution or. alkalis or their aqueous solution in order to maintain the pH of the liquid in the range of 10-1.1 and mixing
    0 mixture until the end of the hydrolysis reaction, usually at a temperature from room temperature to, within 1-8 hours, preferably 2-5 hours.
    After the hydrolysis reaction is completed, the reaction liquid is concentrated, preferably under reduced pressure, and cooled, whereupon the crude product precipitates, which is then collected during filtration. Since the Jewish product contains impurities, including many by-products, for example, the 3-substituted isomer, it is isolated and purified in accordance with the above-described processing methods using column chromatography. This treatment can be used to convert the N, M ,, - disubstituted substance obtained as a by-product in the first of these condensation reactions to the final product.
    The new uracil derivatives of the formula I have a high anticancer activity with weak side effects and are well soluble in the injection medium; therefore, they can be taken orally and as injections.
    Example 1. In a 50 ml dimethyl acetamide solution, 6.50 g (0.05 mol) of 5-fluorouracil is dissolved. Then 15.18 g (0.15 mol) of chloromethyl propionate is added to the solution. The mixtures were kept for 2 hours, the reaction liquid was left to stand overnight and then filtered to remove precipitated hydrochloric triethylamine. Next, dimethylacetamide is distilled off from the filtrate, the residue is treated in a column packed with silica gel and eluted with a mixture of benzene and. ethyl acetate (8: 2-1: 1) the crude 1-propionoxymethyl 5-fluorouradyl is isolated. The crude product is recrystallized from benzene and 7.93 g of pure white crystals are obtained, m.p. 105Yub S.- Yield 73.1%.
    %, C: 44.50; H 4.03; F 8.39; N 12.92.
    CH H, 5FN204.
    Calculated,%: C, 44.45; H 4, ZO; F 8.79; N -12.96.
    NMR spectrum (solvent JlM-SO d) S 1.05 (3N, t, l 3.S.Ne), 2.37 (2H, d, I 8, COCH / p), 5.63 (2H, 5, CH20 ), 8, -18 (d, l 6, С / -Н) and 12.05 {1Н, broad, NH).
    IR spectrum: 3420, 3200, 3080.2930, 1756, 1725, 1704, 1675, 1472, 1468, 1418, 1382, 1360. 1268, 1204, 1175, 1147, 1090, 1018 ,, 962, 900, 842, 812 , 788 and 715cM-t
    Example 2; 80.41 g of dimethylformamide dissolved 10.41 g (0.08 mol) of 5-fluorouracil. Then, 24.29 g (0.24 mol) of triethylamine was added to this solution. Next, 10.93 g (0.08 mol) of butyryloxymethyl chloride is added to the mixture for 15 min. The mixture is kept for 5 hours at room temperature and the reaction liquid is filtered to remove
    precipitated hydrochloric triethylamine. Thereafter, the solvent is distilled off from the filtrate, the residue is treated in a column packed with silica gel, and crude 1-butyryloxymethyl-5-fluorouracil is isolated by elution with a mixture of benzene-ethyl acetate (1: 1). This crude product is recrystallized from benzene to give pure white crystals, m.p. 96-98 ° C. The yield is 86.9%.
    0
    Found,%: C 47.12; H 4.73; F. 8.08; N 12.82 .;
    С (Н „. Calculated,%: с 46.96; H 4.82; F 8.25; N 12.17.
    five
    NMR spectrum (solvent DMSO-d):
    5 0.92 (3H, t, I 8, CH3), 1.60 (2H, t, CH2), 2.35 (2H, t., L 8, COCHj), 5, 6A (2H, S, OCH2 ), 8.17 (lH, d, I 6, - Cx-H) and 12.02 (1H, broad, NHj.
    IR spectrum: 34iO, 3290,3080,2970,
    0 2920, 2830, 1740 (s), 1665, 1472, 1420, 1380, 1350, 1320, 1268, 1250, 1195, 1180, 1145, 1115, 1095,1040
    1000, - 900, 880, 790, 770 and 725 cm.
    Froze 3.90 g (0.03 mol) of 5-fluorouracil- is dissolved in 50 ml of dimethylformamide. Then, 3.0 g of triethylamine was added to this solution, and 4.73 g (O, 0237 mol) of caproyloxymethyl chloride was added dropwise to the mixture. Mixture
    0 hold for 3 h at 50 ° C. At the end of the reaction, the reaction liquid was filtered to remove precipitated hydrochloric triethylamine and the dimethylformamide was removed from the filtrate from 5 by race. Next, 50 ml of chloroform is added to the residue, the mixture is stirred and filtered to remove insoluble, unreacted 5-fluorouracil. Chloroform phase
    0 is washed with water and then dried. After removal of chloroform by distillation, 3.0 g of 1-capryloxymethyl-5-fluorouracil are obtained in the form of white crystals, m.p. 95-9bs .., Yield 38.7%.
    Found%: C. 50.42; H 5.63;
    5 F 7, 1 7; N 1 Oh, 2.
    With „H, 5F.
    Calculated,%: C 51.16; And 5.85; F 7.36; N 10.85.
    NMR (solvent CDClg);
    0,890 (3H, t, l 6, SN3). I.SMAJ, - /.), 1, b2 (2H, t „. COCH2CH), 2, it6 (2H, t, | 6., - COCH, g-), 5.68 (2H, S, N- CH2-), 7.62 (1H, d, I 6,) and 9.85 (1H, broad, NH). IR spectrum:
    5 3420, 3260, 3065, 2940, 2920.2850, 1720; 1684, 1655, 1463, 1408, 1368, 1255, 1200, 1168, 1137, 1108,972 and 780 cm.
    Example4. 4 p t (0.01 mol) of 1 (benzoyloxymethyl) -5-fluorouracil is dissolved in a mixture of 10 ml of pio ridine and 10 ml of water. A 5% aqueous solution of caustic soda is added dropwise to the solution while stirring, half-holding
    CIM way the pH value of the liquid is 10-11. The mixture is kept for 4 hours at 60 ° C ,. as a result of which, “hydronic hydrolysis of the starting 1, 3; -bis- (benz6jjf: 6cmylethyl) -5-fluorouracil occurs. At the end of the hydrolysis, the reaction liquid is concentrated under reduced pressure and ohlahsdayut. The remaining unreacted 1j 3-bis (benzoyloxymethyl) -5-fluorouracil is precipitated and filtered, and the filtrate is subjected to chromatographic treatment using a column filled with silica gel. The mixture of benzene and ethyl acetate is applied (3 : 1) in the quality of the eluent, the desired 1-benzoyloxy-methyl-5-fluorouracil was isolated as the first component of the elution. H-B-enzoxyloxymethyl-5-fluorouracil, obtained as a by-product, is also recovered as the second component of the elution. The yield of 1-benzoyloxymethyl-gb-fluorouracil and 3-benzoyloxymethyl-5-fluorouracil is respectively 0.92 (yield 35%) and O, 65 g. After recrystallization from benzene, 1-benzoyloxymethyl-5-fluorouracil is obtained in the form of white crystals, m.p. 179-180 ° C.
    NMR spectrum. (FlMSO-d solvent): 1-benzoyloxymethyl-5-fluorouracil: 3 5.87 (2H, S, -Cri2-), 7, 8, 1 (5H, m, - ©) S, 27 ( IH, d, l 6,) and 12.00 (1H, broad, NH). IR spectrum: 3410.3385, 3365.3255 1730, 1720, 1700, 1659, 1597, 1463, 1449, 1408, 1372, 1272 , 1260, 1242, 1200, 1165, 1144, 1106,
    1091, 1068, 1041, 1023, 962, 778, 702 cm.
    Example 5. In 100 ml of dimethylacetamide, 19.51 g (0.15 mol) of 5-fluorouracil and 75.90 g (0.75 mol) of triethylamine are dissolved. To this mixture is added dropwise at room temperature 41.05 g (0.165 mol of chloroformate and the mixture is kept for 20 hours. After the reaction with triethyl and dimethylacetamide is removed by distillation and the residue is poured into 400 ml of water. The mixture is stirred, filtered, washed with water and crystals are obtained which are recrystallized from 200 ml of ethanol to give 38.06 g of 1-lauroyloxymethyl-5-fluorouracil, mp 113.7-114, Yield 74.2%.
    Found,%: C 59.94; H 8.16; F 5.52; N 8.07.
    C, 7H27RMg04.
    Calculated,%: C 59.63; H 7.95; F 5.55; N8.19.
    NMR (solvent CDClg,): b 0.88 (3H, t, l aCHj), 1, 24 (iBH.m, (-CH. 9-), 2, 38 (2H, t, l 8 , SOCND), 5, BZ (2H, 5, SLNL) and 7.63 (lH, d, l 6,).
    IR spectrum: 3420,3200,2920 (S), 2850, 1755, 1710 (5), 1b72 ,, 1450, 1372, 1360, 1325. 1267.1205. 1170, (s). 1090,, 1002, 99 980.972, 845, 790, and 720 cm.
    In tab. 1 shows the results of the synthesis of uracil derivatives of General formula 1, as described in examples 1-3 and 5.
    Table 1
    82,8
    H ,,
    73.6
    N C-, N | d
    75.8
    N SdN ,,
    68.0
    N SdI „38,3
    CjH CH
    12 57.0
    sn,
    110 3410,2940,1730 (5), 1692
    1463.1366.1254.1140 and 780
    113 3420.2915.1728 (S), 1693,
    1462.1367.1255, 1140 (5) and 782
    112
    3030, 292S, 1730 (5), 1695, 1468, 1372, 1260.1142 (5) and 785
    3060, 2910, 1720.1693 (5),
    116 1465, 1362, 1260, 1140 (5) and 780 176
    3160, 3040, 1744, 1726, 1695, 1655, 1462, 1373, 1205 (5) and 775
    3170, 3055, 1739 (5X1695,
    0 1657, 1460, 1392.1265 (5), 1170 and 1088 (5)
    Example 13, B70 ml of dimethylacetamide dissolved 2.60 g (0.02 mol) -5-fluorouracil. Therefore, 0.96 g (0.02 mol) of 50% sodium hydride is added to the solution and then a solution of chloromethyl acetate in 10 ml of dimethylacetamide. The mixtures were kept for 5.5 hours at room temperature. At the end of the reaction, the reaction liquid was filtered to remove a precipitate and then the dimethylacetamide, which was used as a solvent, was removed from the filtrate by distillation. The residue is taken up in 100 ml of ether and the ether solution is filtered to remove insoluble products. The ether is removed by distillation and the residue is subjected to adsorption treatment in a column packed with silica gel. The adsorbed substance was eluted with a mixture (1: 1) of benzene and ethyl acetate, and 180 mg of 1,3-bis- (acetoxymethyl) -5-fluorouracil was given in 3.2% yield. This product is a viscous liquid.
    IR spectrum: 3120, 2970, 1755 (5), 1704 (5), 1690 (5), t7B. 1375,1285. 1230 (5), 1170, 1087, 1035 (5), 980, 8k2, 790 and 772cm.
    EXAMPLE 14 Analogously to example 13, but using 6.10 g (O, O2 mol) chloromethyl palmate, instead of chloromethyl acetate, 1.02 g of 1,3-bis (palmityl + oxymethyl) -5-fluorouracil, t .pl. 80-80 ,, yield 15.2%.
    Found,%: С -68,10; H 10.24; F 2, 65; N, b9.
    SaeNb gmgOccalculated,%: P.68,43; H 10.13; F 2.85; N C, 20.
    NMR spectrum (solvent C OS C):: 6 0.87 (6H, t, CHg) 1, 24 (52H, m, CH2), 2.30 (wide: COCH), 5.7l (2H, 5 , CH20), 6.02 (2H, SCH20) and 7.71 (lH, d, l 6, Cx-H).
    IR: 2900, 2830, 1740 (5), 1690 (5), ib, 1355, 1280 ,. 11.62,956 864, 7bO and 72.
    Example 15. 2.60 g (0.02 mol) of 5-fluorouracil was dissolved in 40 ml of dimethylacetamide. Then, 1.52 g (0.011 mol) of powdered potassium carbonate is added to this solution. A solution of 3.31 g (O, 022 mol) of chloromethyltrimethyl acetic acid in 10 ml of dimethylacetamide is added dropwise to the mixture during 1 h.
    The mixture is kept at room temperature for 15.5 hours. At the end of the reaction, the reaction liquid was filtered to remove a precipitate, and then dimethylacetamide, used as a solvent, was removed by distillation. The residue is taken up in 30 ml of ether and, after filtration, the ether is filtered to remove the insoluble matters; the filtrate is concentrated to give 2.52 g of crystals. The latter were recrystallized from ether to obtain 1.88 g of 1,3-bis- (pivaloyloxymethyl) -5-fluorouracil in 47.8% yield as white crystals, mp. 113-114 C.
    Found,%: C 54.02; n 6.69; 5 F A, 99; N 7.72, C | 6H23FN20.
    Calculated,%: C 53.62; H 6.47; F 5.30; N 7.82.
    NMR spectrum: 8 1.17 (9H, 5, CH3), 1.19 ° (9H, 5,). 5.63 (2H, 5, CHji), 5.83 (TH, 5, CHj,) and 7.70 (lH, d, 1.6,).
    IR spectrum: 3420, 2970, 1737 (5),. 1685 (5) ,, 470, 1 366, 1 268, 1130 (5), 1050, 1035, 980, 927.888,
    5 855. 800,77 and 762 cm- ..
    Example 16 7.80 g (0.06 mol) of 5-fluorouracil was dissolved in 100 ml of dimethylformamide. Then, 10.24 g (0.06 mol) of chloromethyl. Benzoate is added to a solution of ext. To this mixture is added dropwise.
     slowly a solution of 6.07 g (0.06 mol) of triethylamine in 10 ml of dimethylformamide. The mixture is allowed to react for 6 hours at room temperature. At the end of the reaction, the reaction liquid was filtered to remove precipitated hydrochloric triethylamine and then dimethylformamide, used as a solvent, was removed from the filtrate by distillation. Remainder
    0 is dissolved in 100 ml of chloroform and the solution is filtered to remove insoluble substances. The filtrate is washed, dried and the chloroform is removed by distillation. The residue is purified on a silica gel column and 2.73 g of 1-benzoyloxymethyl-5-fluorouracil, mp 1778 ° C, and 8.43 g of 1,3-bis- (benzoyloxymethyl) -5-fluorouracil are obtained in the form of a viscous oily substance with yields of 17.1 and 35.4%, respectively.
    0
    NMR spectrum (solvent DMSO-dg):
    S 5.87 (2H, 5, - CH / g-), 7,, 1 (5H, t, -O). 8.27 (IH, d, l 6,) and 12.00 (IL, broad NH.
    IR spectrum: 3410, 3385, 3365.3255, 5 1730, 1720., 1700, 1659, 1597 ,, 1463, 1449, 1408, -. 1372, 1272, 1260,1242
    1200, 1165, - 1144, 1106, 1091, 1068, 1041, .1023, 962, 778, and 702 cm.
    NMR spectrum- (solvent JJM50-d)
    0 1,3-bis- (benzoyloxymethyl) -5-fluorouracil: S 5.5 A. 6.4 (4H, t, -CH2-) and 7.4, 2 (nH.m, -O, -CH- ).
    And -spectrum: 3110, 3078.3000, 1768, 1755, 1743, 1707, 1608, 1591, 1462,
    5 1381, 1229, 1270, 1190, 1169,1100, 1073, 1055, 1032, 984,770,714, and 692 cm.
    Example 17. 2.74 g (0.01 mol) of 2 was dissolved in 20 ml of chloroform. -bis (trimethylsilyl) -5-fluorouracil and 2.71 g (0.013 mol) of benzaldiacetate. A solution of 2 g of tin tetrachloride in 10 ml of chloroform is slowly added dropwise to this mixture.
    After addition of the solution, chloroform is removed by distillation and the residue is extracted with water. The residue from extraction is dissolved in chloroform, then chloroform is distilled off. The residue was redissolved in a small amount of chloroform, petroleum ether was added to the solution, and the resulting precipitate was collected via a filter. In this way, 1.06 g of 1- (i-acetoxy-e-phenyl) -methyl-5 fluorouracil is obtained, m.p. 172-17bs.
    PUME spectrum (solvent flMSO-d): 2,, CH2,), 7.53 (5H, S, © K 7.82 (IH, S, CH), 7.91 (IH, d, l 6,) and 1 2, 2 (I H, wide NH).
    Infrared technology: 3200, 3075, 2830.1765; 1732, 1700 (S): 1657, 1467.1378.1256, 1200, IITIH-, 1020, 980,897,782,720 and 690 cm.
    The proposed uracil derivatives are tested by the method below to determine their antitumor activity as a percentage of life increase (ELS) widely adopted for the evaluation of antitumor activity. The test results are presented in table. 2
    In a group of six BDFy mice, each mouse was infected by injecting into the peritoneum 1x10 cancer cells of lymphatic leukemia (strain of the National Cancer Institute) 24 hours after infection, mice were injected once into the peritoneum into the peritoneum or a certain amount of 6.5 was suspended in the gut. % CMC. within 5 days and write down the number of days of life. The ELS is calculated according to the following equation depending on the number of days of life of the control group of mice:
    T - the number of days from the first day
    administering the test compound to the days of death of the infected mice С - number of days from the first day
    infection before the day of death of the control group of mice that received placebo.
    Table
    ,
    H-CgH
    ,
    CH-J
    CH,
    44 16
    19 23 29
    45 40
    ten
    12
    25
    106
    34
    20 31
    43 29
    From tab. 2 that new uracil derivatives show high antitumor activity and are therefore suitable as antitumor agents.
    Comparative example, In a group of 6 rats, each rat is injected 30 times.
    Note; 1. Compounds labeled with stars. Reduction n.o. means From tab. 3.It follows that 1-acetoxymethyl-5-fluorouracil as a known compound with a similar
    Continued table. 2
    penetration into the peritoneum is a test substance at the rate of 50 ml / kg of live weight, after which the changes in the concentration of the test compound in the blood over a period of time are studied. The results of this study are shown in Table 3.
    Table 3 by the daughter, are known. not found. application is characterized by a strong T9 toxicity, a rapid decrease in the 45 concentration in the blood and a weak
    权利要求:
    Claims (10)
    [1]
    Claim
    1. The method of obtaining derivatives of uracil of General formula (t) b
    F where '. R 2 is a hydrogen atom or a group of the formula
    The method of pop. 1, characterized in that the reaction of the presence of a binding kis-CH-0-C-R ^;
    I η and 2 R 0.
    R * is a hydrogen atom, alkyl C | -C ^, or phenyl); fi - alkyl C; -C ig (or phenyl under the condition that when R ^ is hydrogen, R 3 is phenyl or straight-chain C ^ -C ^, characterized in that 5-fluorouracil is reacted with haloalkylcarboxylate of the formula
    O - s - R 3 and
    the above values X - CH 1 2
    R z
    [2]
    2 3 where R HR have the terms and X represents a halogen atom, followed by isolation of the target product or subsequent hydrolysis of the obtained It, s ^ -substituted cyclic of formula 0
    II to 5 - s - o - g
    II
    1 0
    CH-OC-RS » 1 h n k 2 o ur45
    2 3 where R HR have the above meanings, by the action of acid or urine to obtain compounds of mule I, where R 4 'is hydrogen.
    2. The method according to claim 1, with the fact that chloromethyl acetate, chloromethylpropio are used as αό -haloalkylcarboxylate. nat ', chloromethyl butyrate, chloromethylcapronate) chloromethylaprilate, chloromethyl laurate, chloromethyl palmiate, chloromethyl pivalate or chloromethylbenzoate.
    [3]
    3.
    They also contain an agent and a polar solvent inert in this reaction and capable of dissolving -5-fluorouracil.
    [4]
    4. The method according to claim 1, characterized in that the reaction is carried out at a temperature of from 0 to 100 ° C for 1-20 hours
    [5]
    5. The method of pop.Z, characterized in that an aliphatic or aromatic tertiary amine is used as the acid binding agent.
    [6]
    6. The method of pop.Z, distinguished by the fact that an inorganic base is used as the acid binding agent.
    [7]
    7. The method of pop. 1, characterized in that the target derivatives of uracil are separated from the reaction mixture by chromatographic treatment.
    [8]
    8. The method of pop. 1, characterized in that the acid used is a strong inorganic acid or its aqueous solution.
    [9]
    9. The method according to claim 1, characterized in that caustic alkali or its aqueous solution is used as alkali.
    [10]
    10. I y u and y 'dyat during the course
    The method of pop. 1, distinguished by the fact that hydrolysis is carried out at a temperature of 0 to 10 ° C in 1-10 hours.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU795468A3|1981-01-07|Method of preparing uracyl derivatives
    EA007953B1|2007-02-27|Processes for the preparation of 4-[[4-[[-4-|-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
    KR930002492B1|1993-04-02|Process for preparation of 6-thioxanthine derivatives
    US3238224A|1966-03-01|Production of 6, 8-dithiooctanoyl amides
    DE69629341T2|2004-06-09|PYRROLOCARBAZOLDERIVATE
    SK14672001A3|2002-11-06|Novel synthesis and crystallization of piperazine ring-containing compounds
    EP0009608B1|1982-04-21|N-phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them
    KR900003497B1|1990-05-21|Quinazoline diones and pyrido pyrimidine-diones and its pharmaceutical composition
    US3813398A|1974-05-28|Benzenesulfonyl-semicarbazides and process for their manufacture
    EP0223647B1|1990-08-01|Alkyl carboxamides of pyridyl alkyl amines, their preparation and their use as medicaments
    KR880001715B1|1988-09-08|Process for preparing 1-furyl-3,4-dihydro-isoquinolines
    US2501858A|1950-03-28|4&#39;|-morpholine ester of nicotinic acid and its production
    JP3009716B2|2000-02-14|New camptothecin derivatives
    EP0062068B1|1985-06-12|N-phthalidyl-5-fluorouracil derivatives
    RU2733731C1|2020-10-06|Method of producing intermediate products for synthesis of kalanolides and analogues thereof
    US3105834A|1963-10-01|2-|-imidazo [1, 2-alpha]-pyridine or-pyrimidine
    DE2416355A1|1974-10-24|DIRECT SYNTHESIS OF DOPAMINE AMINO ACID AMIDES
    US4231933A|1980-11-04|Novel 3-hydroxy-pyrrolin-2-one derivatives
    KR950005737B1|1995-05-30|Separating method of component from gingkolide complex
    JPH0674260B2|1994-09-21|Quinoline derivatives, their esters and their salts
    EP0178073B1|1988-04-27|Amide compounds, process for preparing the same and pharmaceutical compositions containing the same
    SU440835A1|1974-08-25|METHOD FOR OBTAINING SUBSTITUTED QUINOLINES1 The invention relates to a method for producing new compounds that can be used in medicine. The high reactivity of halogen atoms in position 4 of the quinoline core with respect to amines is known. A method is proposed for producing a series of new compounds possessing valuable biological activity using a reaction known in organic chemistry. The described method for producing substituted quinolins of the general formula R.-FlC ^ c- ^ ujruIFT ^ E, where Cs is hydrogen or lower alkyl, or Y - 4, 5-disubstituted groups, derivatives of 2-p-thiazoles of formula 10
    KR800001594B1|1980-12-29|Process for preparing 5-fluoro uracils
    JP2706554B2|1998-01-28|4-trifluoromethylaniline derivative and method for producing the same
    JP2800939B2|1998-09-21|Tricyclic compounds, esters and salts thereof
    同族专利:
    公开号 | 公开日
    FI62071B|1982-07-30|
    DK142413C|1981-03-23|
    AU513153B2|1980-11-20|
    NL7709808A|1978-03-08|
    GB1543467A|1979-04-04|
    SE438856B|1985-05-13|
    ZA775361B|1978-07-26|
    FI62071C|1982-11-10|
    DK142413B|1980-10-27|
    PL108914B1|1980-05-31|
    CH634567A5|1983-02-15|
    US4267326A|1981-05-12|
    FI772594A|1978-03-07|
    JPS6114148B2|1986-04-17|
    HU177482B|1981-10-28|
    SE7709942L|1978-03-07|
    JPS5331676A|1978-03-25|
    PH14000A|1980-11-28|
    DK394477A|1978-03-07|
    FR2363563A1|1978-03-31|
    PL200685A1|1978-10-09|
    FR2363563B1|1980-06-20|
    DE2739912A1|1978-03-09|
    AU2857177A|1979-03-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS5324952B2|1973-11-28|1978-07-24|
    JPS603071B2|1975-02-17|1985-01-25|Mitsui Seiyaku Kogyo Kk|
    DK1951658T3|2005-11-17|2012-10-15|Lilly Co Eli|GLUCAGON RECEPTOR ANTAGONISTS, MANUFACTURING AND THERAPEUTIC APPLICATIONS|JPS5716991B2|1976-12-23|1982-04-08|
    JPS54122281A|1978-03-13|1979-09-21|Mitsui Toatsu Chem Inc|5-fluorouracil derivative and its preparation|
    JPS5668674A|1979-11-08|1981-06-09|Shionogi & Co Ltd|5-fluorouracil derivative|
    JPS5724369A|1980-07-19|1982-02-08|Tokyo Kinzoku Kogyo Kk|Pyrimidine derivative and its preparation|
    JPH0140830B2|1980-08-19|1989-08-31|Chugai Pharmaceutical Co Ltd|
    EP0162924B1|1983-10-20|1989-12-13|Terumo Kabushiki Kaisha|5-fluorouracil derivatives and medicinal preparation containing same|
    DK197486A|1986-04-30|1987-10-31|Ferring Farma Lab|5-FLUORURACIL PRODUCT|
    US6051576A|1994-01-28|2000-04-18|University Of Kentucky Research Foundation|Means to achieve sustained release of synergistic drugs by conjugation|
    PT2445502T|2009-06-25|2017-09-22|Alkermes Pharma Ireland Ltd|Heterocyclic compounds for the treatment of neurological and psychological disorders|
    CA2766033C|2009-06-25|2016-09-20|Alkermes, Inc.|Prodrugs of nh-acidic compounds|
    NZ748572A|2012-09-19|2020-07-31|Alkermes Pharma Ireland Ltd|Pharmaceutical compositions having improved storage stability|
    CN110368360A|2014-03-20|2019-10-25|奥克梅斯制药爱尔兰有限公司|Aripiprazole formulations with increased injection speed|
    CN109761915B|2019-03-05|2021-12-21|沈阳药科大学|5-fluorouracil ester-forming prodrugs targeting the MCT1 transporter|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP51105714A|JPS6114148B2|1976-09-06|1976-09-06|
    [返回顶部]